Internet Computer ICP

Bitcoin Cash BCH

Litecoin LTC

Laekna Inc

2105

Current price

10.76 HKD -0.2 HKD (-1.82%)

Last closed 11.06 HKD

Company www.laekna.com

ISIN unknown

Sector Healthcare

Industry Biotechnology

Exchange Hong Kong Stock Exchange

Capitalization 4 633 520 885 HKD

Yield for 12 month -17.86 %

10Y

15Y

2105

21.11.2021 - 28.11.2021

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China. Address: 3-2-467, 5 Xingbin Road, Yuyao, China

Check your investment idea

Find the best to beat the market

TSLA Tesla Motors

AAPL Apple

MSFT Microsoft

Activate

View

Activate

View

Analytics

WallStreet Target Price

–

P/E ratio

19.59

Dividend Yield

–

Revenue
Profit

Current Year

–

Last Year

–

Current Quarter

–

Last Quarter

–

Current Year

–

Last Year

–

Current Quarter

–

Last Quarter

–

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

EBITDA -322 398 121 HKD

Operating Margin TTM -38 454.68 %

PE Ratio 19.59

Return On Assets TTM -21.55 %

PEG Ratio –

Return On Equity TTM -36.08 %

Wall Street Target Price –

Revenue TTM 657 233 HKD

Book Value 1.90 HKD

Revenue Per Share TTM

Dividend Share –

Quarterly Revenue Growth YOY 85.40 %

Dividend Yield –

Gross Profit TTM –

Earnings per share –

Diluted Eps TTM –

Most Recent Quarter II 2024

Quarterly Earnings Growth YOY –

Profit Margin –

Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

–

5Y Dividend Growth

–

Consecutive Years

–

5Y Average Payout Ratio

–

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

Forward Annual Dividend Rate –

Ex Dividend Date –

Forward Annual Dividend Yield –

Last Split Factor –

Payout Ratio –

Last Split Date –

Dividend Date –

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

Trailing PE 19.59

Forward PE –

Enterprise Value Revenue –

Price Sales TTM 7 050.05

Enterprise Value EBITDA –

Price Book MRQ 7.10

Financials 2105

1 year

3 years

5 years

10 years

15 years

Track key metrics for each stock in one place without the hassle

Get Premium

Results	2019	Dynamics

* The data for this period has not yet been published

3.15 HKD 17.79 HKD

50 Day MA 11.83 HKD

Shares Short Prior Month –

200 Day MA 7.28 HKD

Short Ratio –

Shares Short –

Short Percent –

	All Time	January, 22	February, 22	March, 22	April, 22	May, 22	June, 22
Companies with BMS 90+	+10.12%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%
Companies with BMS 60-	+10.12%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%

Similar to

Laekna Inc